Document is current

Article History

Received: 13 January 2024

Accepted: 12 June 2024

First Online: 19 June 2024

Declarations

:

: This study was conducted in compliance with Good Clinical Practice and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements. The study was approved by the Ethic Committee of the University of Duisburg-Essen (23–11248-BO) as well as by the Ethic Committees of the Medical School Hannover, and the Universities of Cologne and Ulm. Due to the retrospective character of the study need to consent was waived.

: Not applicable.

: K.S. and H.R. declare no competing interests. L.K. has received consulting fees from Alexion and research funding from Sanofi-Genzyme. L.S.K. reports consultant honoraria and travel grants from Alexion. J.K. reports speaker honoraria and participation in advisory boards from Alexion, Sanofi, and Chiesi. A.K. has received grants for clinical studies, speaker fees, honoraria and travel expenses from Actelion, Amgen, Amicus, Alexion, Astellas, Bayer, Baxter, Binding Site, Bristol-Myers Squibb, Chiesi, CytoSorbents, Fresenius, GlaxoSmithKline, Hexal, Janssen, Kyowa Kirin, MSD, Novartis, Otsuka, Peripal, Pfizer, Roche, Sanofi, Shire, Teva and Vifor Fresenius Medical. B.S. has received consultant/speaker honoraria from Alexion, Amgen, Novartis, Astellas, Bristol Myers Squibb, Boehringer Ingelheim, Bayer, Vifor Pharma, Astra Zeneca, Janssen-Cilag, Pfizer, GlaxoSmithKlein, Lilly. P.T.B. has received speaker honoraria and consultant fees from Sanofi-Genzyme, AstraZeneca, Alexion, Bayer, Travere, Pfizer, Novartis, Roche, Boehringer Ingelheim, and participated in advisory boards for Alexion, Sanofi-Genzyme, Novartis, Travere, and Bayer. A.G. has received speaker/consultant honoraria and study fees from Alexion/Astra Zeneca, Boehringer Ingelheim, Chiesi, Novartis, Sanofi, Roche and Vifor Pharma.